North American Scientific to Hold Conference Call and Webcast on Third Quarter Fiscal Year 2008 Financial Results on Thursday, September 11, 2008
CHATSWORTH, Calif.--North American Scientific, Inc. (Nasdaq:NASM - News) announced today that it will issue results for the third quarter of fiscal year 2008, which ended July 31, 2008, at market close on Thursday, September 11, 2008. The Company will host an investor conference call to review its third quarter fiscal year 2008 financial results and latest corporate developments, beginning at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, September 11, 2008. The dial-in number for the conference call is 866-383-8108 for domestic participants and 617-597-5343 for international participants, using the pass code 61406061.
A taped replay of the call will be available beginning approximately one hour after the call’s conclusion and will remain available for seven days. It can be accessed by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers, using the pass code 73033977. A live webcast of North American Scientific’s conference call will be available over the Internet through its website at www.nasmedical.com in the Investor Center. For those who cannot listen to the live webcast, a replay of the call will be available at the same site shortly after the call.
About North American Scientific
North American Scientific is a leader in radiation therapy in the fight against cancer. Its innovative products provide physicians with tools for the treatment of various types of cancers. They include Prospera® brachytherapy seeds and SurTRAK™ needles and strands used primarily in the treatment of prostate cancer. In addition, the Company has been gaining clinical experience with its first generation ClearPath™ multi-channel catheter breast brachytherapy devices in 2007, and intends to launch the second generation devices in 2008. They are the only such devices approved for both high dose and continuous release, or low dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer the more advanced form of brachytherapy for the treatment of breast cancer. Please visit www.nasmedical.com for more information.
Click here to access the webcast.
